Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 3/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | TOP1 | P11387 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14248985 | 0.87 | KMT2A (0.63) | KMT2AMAPTSMN1; SMN2ESR1ESR2 | |
| SCHEMBL27738180 | 0.83 | KMT2A (0.54) | KMT2AMAPTSMN1; SMN2ESR1ESR2 | |
| SCHEMBL11411081 | 0.81 | KMT2A (0.38) | KMT2AMAPTSMN1; SMN2ESR1HSD17B10 | |
| SCHEMBL31389161 | 0.81 | KMT2A (0.38) | KMT2AMAPTSMN1; SMN2ESR1HSD17B10 | |
| SCHEMBL725404 | 0.80 | KMT2A (0.76) | KMT2AMAPTSMN1; SMN2ESR1ESR2 | |
| SCHEMBL18263212 | 0.79 | LMNA (0.50) | KMT2AMAPTSMN1; SMN2ESR1ESR2 | |
| SCHEMBL3153215 | 0.79 | KMT2A (0.50) | KMT2AMAPTSMN1; SMN2ESR1ESR2 | |
| SCHEMBL10964989 | 0.79 | KDM4E (0.36) | KMT2AMAPTSMN1; SMN2ESR1ESR2 | |
| Bromide SCHEMBL29588519 | 0.78 | KMT2A (0.73) | KMT2AMAPTSMN1; SMN2ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL16050041 | 0.78 | KMT2A (0.73) | KMT2AMAPTSMN1; SMN2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250333447-A1 | CHIMERIC SMALL MOLECULES FOR LABELING PROTEINS WITH IMMUNOGENIC MOIETIES AND METHODS OF USE THEREOF | BRIGHAM & WOMENS HOSPITAL INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250277062-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12404348-B2 | Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4602079-A2 | CHIMERIC SMALL MOLECULES FOR LABELING PROTEINS WITH IMMUNOGENIC MOIETIES AND METHODS OF USE THEREOF | The Brigham & Women's Hospital, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250255875-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2025-08-14 | — | — | US | disclosed |
| EP-4598633-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | The Brigham & Women's Hospital, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025128165-A2 | ELECTROPHILIC REACTIVE LINKERS FOR LABELING OF POLYPEPTIDES AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250195668-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4433458-A2 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | The Broad Institute, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-4267186-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | Yeda Research and Development Co. Ltd (IL) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023196991-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-116669770-A | Methacrylamide protein binding agents and uses thereof | 耶达研究与发展有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023092094-A2 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| WO-2022225728-A9 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022225728-A2 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022137240-A1 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021055690-A1 | PEPTIDE-CONJUGATED PRODRUGS | BRANDEIS UNIVERSITY (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | KMT2A 1801/4885MAPT 3330/4885SMN1; SMN2 4135/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | KMT2A 4547/4885MAPT 4191/4885SMN1; SMN2 3023/4885 |
| US-20250195668-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | KMT2A 2272/4885MAPT 3572/4885SMN1; SMN2 3607/4885 |
| US-20250277062-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | KMT2A 1636/4885MAPT 3770/4885SMN1; SMN2 3469/4885 |
| US-20250255875-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | KMT2A 1636/4885MAPT 3770/4885SMN1; SMN2 3469/4885 |
| US-12404348-B2 | Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof | ERBB2, ACP1, TK1 | KMT2A 1636/4885MAPT 3770/4885SMN1; SMN2 3469/4885 |
| US-20250333447-A1 | CHIMERIC SMALL MOLECULES FOR LABELING PROTEINS WITH IMMUNOGENIC MOIETIES AND METHODS OF USE THEREOF | CD74, MICA, HLA-C | KMT2A 2908/4885MAPT 2359/4885SMN1; SMN2 4625/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | KMT2A 1636/4885MAPT 3770/4885SMN1; SMN2 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.